Junping Kou Selected Research

blebbistatin

1/2022	The myosin II inhibitor, blebbistatin, ameliorates pulmonary endothelial barrier dysfunction in acute lung injury induced by LPS via NMMHC IIA/Wnt5a/β-catenin pathway.
2/2020	An inhibitor of myosin II, blebbistatin, suppresses development of arterial thrombosis.
1/2020	NMMHC IIA triggers neuronal autophagic cell death by promoting F-actin-dependent ATG9A trafficking in cerebral ischemia/reperfusion.
1/2017	The Myosin II Inhibitor, Blebbistatin, Ameliorates FeCl3-induced Arterial Thrombosis via the GSK3β-NF-κB Pathway.
7/2015	NMMHC IIA inhibition impedes tissue factor expression and venous thrombosis via Akt/GSK3β-NF-κB signalling pathways in the endothelium.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Junping Kou Research Topics

Disease

18	Inflammation (Inflammations) 01/2022 - 04/2003
11	Cardiovascular Diseases (Cardiovascular Disease) 03/2022 - 03/2011
10	Neoplasms (Cancer) 06/2022 - 09/2011
10	Brain Ischemia (Cerebral Ischemia) 01/2022 - 08/2013
9	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022 - 08/2013
8	Acute Lung Injury 01/2022 - 01/2012
8	Reperfusion Injury 12/2021 - 10/2014
7	Myocardial Ischemia (Ischemic Heart Diseases) 03/2022 - 11/2016
7	Infarction (Infarctions) 01/2022 - 08/2013
6	Thrombosis (Thrombus) 02/2020 - 06/2006
6	Insulin Resistance 08/2019 - 07/2011
5	Ischemia 01/2020 - 08/2013
5	Edema (Dropsy) 08/2016 - 01/2005
4	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 09/2005
4	Sepsis (Septicemia) 06/2021 - 08/2006
4	Neoplasm Metastasis (Metastasis) 01/2020 - 09/2011
4	Heart Failure 05/2019 - 05/2016
3	Pheochromocytoma 01/2022 - 01/2016
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2022 - 01/2016
3	Hypoxia (Hypoxemia) 01/2019 - 01/2011
3	Pulmonary Edema 08/2016 - 01/2012
2	Brain Injuries (Brain Injury) 01/2021 - 01/2021
2	Myocardial Infarction 01/2021 - 04/2020
2	Herpes Zoster 01/2020 - 01/2016
2	Ischemic Stroke 01/2020 - 01/2017
2	Brain Infarction 06/2019 - 08/2016
2	Brain Edema (Cerebral Edema) 06/2019 - 01/2016
2	Fibrosis (Cirrhosis) 05/2019 - 01/2016
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2019 - 01/2017
2	Central Nervous System Diseases (CNS Diseases) 01/2017 - 01/2016
2	Dysmenorrhea (Menstrual Pain) 09/2016 - 06/2015
1	Pulmonary Embolism 01/2022
1	Lung Injury 01/2022
1	Pathologic Constriction (Stenosis) 01/2022

Drug/Important Bio-Agent (IBA)

14	ruscogeninIBA 03/2022 - 07/2005
11	Glucose (Dextrose)FDA LinkGeneric 03/2022 - 01/2016
10	Oxygen (Dioxygen)IBA 03/2022 - 01/2016
10	radix ophiopogonis drug combination radix ginseng fructus schizandrae (Shen Mai)IBA 01/2022 - 12/2015
8	yi-qi-fu-maiIBA 01/2022 - 01/2016
7	Neuroprotective AgentsIBA 01/2022 - 10/2014
7	PowdersIBA 01/2020 - 01/2016
6	LipopolysaccharidesIBA 06/2021 - 05/2008
6	Pharmaceutical PreparationsIBA 04/2019 - 01/2005
5	blebbistatinIBA 01/2022 - 07/2015
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2015
5	Thromboplastin (Tissue Factor)IBA 02/2020 - 03/2011
4	ginsenoside Rb1IBA 03/2022 - 12/2015
4	Myosin Type IIIBA 01/2022 - 01/2017
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2020 - 09/2005
4	CytokinesIBA 02/2020 - 07/2011
4	SaponinsIBA 01/2020 - 09/2011
4	CarrageenanIBA 05/2008 - 07/2005
4	Xylenes (Xylene)IBA 05/2008 - 04/2003
3	CateninsIBA 01/2022 - 05/2019
3	Therapeutic UsesIBA 01/2022 - 06/2015
3	schizandrinIBA 01/2021 - 12/2015
3	Hematoxylin (Haematoxylon)IBA 01/2021 - 05/2019
3	Evans Blue (Blue, Evans)FDA Link 01/2021 - 01/2016
3	Eosine Yellowish-(YS) (Eosin)IBA 01/2021 - 05/2019
3	Myosin Heavy Chains (Myosin Heavy Chain)IBA 01/2021 - 07/2015
3	Insulin (Novolin)FDA Link 03/2016 - 07/2011
3	DiosgeninIBA 01/2016 - 08/2012
3	ophiopogonin DIBA 07/2015 - 07/2005
3	danggui-shaoyao-sanIBA 06/2015 - 02/2005
3	Analgesics (Analgesic Drugs)IBA 01/2014 - 01/2005
3	Acetic Acid (Vinegar)FDA LinkGeneric 05/2008 - 01/2005
2	GlutaminaseIBA 06/2022 - 01/2021
2	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 01/2020
2	Coloring Agents (Dyes)IBA 01/2021 - 01/2005
2	triphenyltetrazoliumIBA 01/2021 - 01/2021
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 04/2020 - 12/2016
2	Creatine Kinase (Creatine Phosphokinase)IBA 04/2020 - 12/2016
2	Particulate MatterIBA 12/2019 - 12/2018
2	GinsenosidesIBA 08/2019 - 05/2019
2	LipidsIBA 08/2019 - 05/2019
2	Palmitic Acid (Hexadecanoic Acid)IBA 05/2019 - 01/2016
2	Dynamins (Dynamin)IBA 01/2019 - 01/2017
2	Nonmuscle Myosin Type IIAIBA 11/2018 - 01/2016
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 05/2008
2	Adenosine Triphosphate (ATP)IBA 01/2017 - 01/2016
2	InflammasomesIBA 08/2016 - 09/2015
2	Biomarkers (Surrogate Marker)IBA 05/2016 - 04/2016
2	QuercetinIBA 03/2016 - 12/2014
2	AdipokinesIBA 01/2016 - 11/2014
2	Sirtuin 1IBA 01/2016 - 11/2014
2	PalmitatesIBA 08/2012 - 05/2012
2	Ethanol (Ethyl Alcohol)IBA 05/2008 - 09/2005
2	Histamine (Histamine Dihydrochloride)FDA Link 09/2006 - 04/2003
1	TubulinIBA 04/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2021
1	cadherin 5IBA 06/2021
1	Drug CombinationsIBA 01/2021
1	NF-kappa B (NF-kB)IBA 01/2021

Therapy/Procedure

13	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022 - 08/2006
7	Oral Administration 08/2016 - 09/2005
5	Therapeutics 06/2022 - 01/2012
5	Ligation 01/2019 - 09/2005
3	Intravenous Injections 08/2016 - 01/2012
2	Ischemic Postconditioning 12/2021 - 11/2016